ClinicalTrials.gg
TerminatedNCT03569007Updated Jul 26, 2022

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

A Phase 3 interventional study of Larazotide and Matching Placebo in Celiac Disease, sponsored by 9 Meters Biopharma, Inc.. Terminated at 160 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-26.

Sponsored by 9 Meters Biopharma, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Trial terminated by Sponsor

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
5th of 68
307 · median 46
Started
2019
with 4 others
Phase 3
2 of 103
none open now
Registered
56th of 103
by date
Lead sponsor
8 of 103
9 Meters Biopharma, Inc.

Among the 103 studies in Celiac Disease with a site in United States, this one is the 5th largest by enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2019, is one of 2 in phase 3, and was the 56th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.

Read the detailed description

This is a phase 3, randomized, double-blind, placebo-controlled, multicenter, outpatient study to evaluate the efficacy and safety of larazotide acetate for the relief of persistent symptoms in adult patients with celiac disease on a gluten free diet.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults diagnosed with celiac disease (positive celiac serology plus confirmed ) for at least 6 months
  • On a gluten-free diet for at least 6 months
  • Experiencing symptoms (ie, abdominal pain, abdominal cramping, bloating, gas, diarrhea, loose stool, or nausea)
  • Willing to maintain current gluten-free diet throughout participation in the study

Exclusion criteria

Exclusion Criteria:

  • celiac disease or severe complications of celiac disease
  • Chronic active GI disease other than celiac disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
307 participants (actual)

Study arms

  • Active comparator
    Larazotide 0.25 mg

    Larazotide 0.25 mg capsules TID

    Drug: Larazotide

  • Active comparator
    Larazotide 0.50 mg

    Larazotide 0.50 mg capsules TID

    Drug: Larazotide

  • Placebo comparator
    Placebo

    Matching placebo capsules TID

    Drug: Matching Placebo

Interventions

  • Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules

    Also known as: INN-202

  • DrugMatching Placebo

    enteric-coated beads in gelatin capsules

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who are binary responders

    Reduction in CeD PRO Abdominal Domain scores

    Time frame: 12 weeks

07

Study locations

160 sites
  • Research Site
    Saraland, Alabama 36571, United States
  • Research Site
    Scottsdale, Arizona 85251, United States
  • Research Site
    Tucson, Arizona 85712, United States
  • Research Site
    Tucson, Arizona 85745, United States
  • Research Site
    North Little Rock, Arkansas 72117, United States
  • Research Site
    Bellflower, California 90706, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Canoga Park, California 91303, United States
  • Research Site
    Corona, California 92879, United States
  • Research Site
    Garden Grove, California 92845, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Los Gatos, California 95032, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Poway, California 92064, United States
  • Research Site
    Rialto, California 92377, United States
  • Research Site
    San Diego, California 92013, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Francisco, California 94102, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Bridgeport, Connecticut 06606, United States
  • Research Site
    Bristol, Connecticut 06010, United States
  • Research Site
    Hamden, Connecticut 06518, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Inverness, Florida 34452, United States
  • Research Site
    Lakewood Ranch, Florida 34211, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Orange Park, Florida 32073, United States
  • Research Site
    Orlando, Florida 32803, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Macon, Georgia 31201, United States
  • Research Site
    Stockbridge, Georgia 30281, United States
  • Research Site
    Stone Mountain, Georgia 30083, United States
  • Research Site
    Sugar Hill, Georgia 30518, United States
  • Research Site
    Boise, Idaho 83706, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Arlington Heights, Illinois 60005, United States
  • Research Site
    Fairview Heights, Illinois 62208, United States
  • Research Site
    Melrose Park, Illinois 60160, United States
  • Research Site
    Morton, Illinois 61550, United States
  • Research Site
    Clive, Iowa 50325, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    West Des Moines, Iowa 50266, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Lexington, Kentucky 40509, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Crowley, Louisiana 70526, United States
  • Research Site
    Lafayette, Louisiana 70503, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    New Orleans, Louisiana 70125, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21208, United States
  • Research Site
    Catonsville, Maryland 21228, United States
  • Research Site
    Columbia, Maryland 21045, United States
  • Research Site
    Hagerstown, Maryland 21742, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Fall River, Massachusetts 02723, United States
  • Research Site
    Chesterfield, Michigan 48047, United States
  • Research Site
    Rochester, Michigan 48307, United States
  • Research Site
    Wyoming, Michigan 49519, United States
  • Research Site
    Jackson, Minnesota 39216, United States
  • Research Site
    Maplewood, Minnesota 55117, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Petal, Mississippi 39465, United States
  • Research Site
    Jefferson City, Missouri 65109, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Las Vegas, Nevada 89109, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    Portsmouth, New Hampshire 03801, United States
  • Research Site
    Freehold, New Jersey 07728, United States
  • Research Site
    Ocean Township, New Jersey 07712, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    Great Neck, New York 11023, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    New Windsor, New York 12553, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 11419, United States
  • Research Site
    Poughkeepsie, New York 12601, United States
  • Research Site
    Williamsville, New York 14221, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Concord, North Carolina 28025, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Salisbury, North Carolina 28144, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45215, United States
  • Research Site
    Cincinnati, Ohio 45219, United States

Showing the first 100 of 160 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jul 2022, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jun 26, 2018
StartActual
May 29, 2019
Primary completionActual
Jul 21, 2022
CompletionActual
Jul 21, 2022
Last update
Jul 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03569007
Lead sponsor
9 Meters Biopharma, Inc.
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
May 29, 2019
Primary completion
Jul 21, 2022
Completion
Jul 21, 2022
Last update
Jul 26, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide

Start the discussion